TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03204565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanced flap
Description: coronally advanced flap alone (CAF- control)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
Study: NCT01402479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: ramipril 2.5mg twice a day
Study: NCT02703246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal morcellation
Description: patients will be randomized to receive abdominal morcellation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal morcellation
Description: patients will be randomized to receive vaginal morcellation
Study: NCT02530177

Intervention type: BEHAVIORAL
Intervention: Questionnaires

Intervention type: BEHAVIORAL
Intervention: Questionnaires

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Study: NCT02567214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultibro®
Description: The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva®
Description: The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
Study: NCT02530177

Intervention type: OTHER
Intervention: Saliva sample
Description: (only once, preferably at baseline)
Study: NCT00701155

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
Study: NCT01892449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prolonged inspiratory to expiratory (I:E) ratio (1:1)
Description: 80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the prolonged I:E ratio (1:1), mechanical ventilation is maintained with during I:E ratio 1:1 during steep trendelenburg with pneumoperitoneum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional I:E ratio (1:2)
Description: 80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the conventional I:E ratio (1:2) group (n=40), mechanical ventilation is maintained with during I:E ratio 1:2 during steep trendelenburg with pneumoperitoneum.
Study: NCT03555188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron is a highly selective receptor antagonist (5-HT3RA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron is a highly selective receptor antagonist (5-HT3RA)
Study: NCT02530177

Intervention type: OTHER
Intervention: Saliva sample
Description: (only once, preferably at baseline)

Intervention type: OTHER
Intervention: Saliva sample
Description: (only once, preferably at baseline)
Study: NCT00594204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline tartrate (CP-526, 555-18)
Description: 1 mg twice a day for 12 weeks, starting with a 1-week titration period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo 1 tablet twice a day for 12 weeks
Study: NCT01975233

Intervention type: DEVICE
Intervention: WEB Aneurysm Embolization System
Description: WEB Aneurysm Embolization System
Study: NCT04407455

Intervention type: DIAGNOSTIC_TEST
Intervention: Karaduman Chewing Performance Scale
Description: For chewing evaluation, children will be asked to bite and chew a standardized biscuit. Each chewing evaluation will be scored according to the KCPS.
Study: NCT04883476

Intervention type: OTHER
Intervention: Observation study only
Study: NCT03983681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy-Based Training to Enhance Memory (STEM)
Description: Protocol designed to improve memory functioning in individuals with neurological injuries administered for 4 weeks (8 training sessions).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control exercises
Description: Placebo control memory exercises will be administered for 4 weeks (8 training sessions).
Study: NCT01049503

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fluoride and conventional dentifrices with different pH
Description: Comparison of different dentifrice fluoride concentrations and pH on caries control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fluoride and conventional dentifrices with different pH
Description: Comparison of different dentifrice fluoride concentrations and pH on caries control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fluoride and conventional dentifrices with different pH
Description: Comparison of different dentifrice fluoride concentrations and pH on caries control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fluoride and conventional dentifrices with different pH
Description: Comparison of different dentifrice fluoride concentrations and pH on caries control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fluoride and conventional dentifrices with different pH
Description: Comparison of different dentifrice fluoride concentrations and pH on caries control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fluoride and conventional dentifrices with different pH
Description: Comparison of different dentifrice fluoride concentrations and pH on caries control
Study: NCT00726596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
Study: NCT02788604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Summary of psychosocial risk factors
Description: The treatment team will receive a psychosocial risk summary shortly following diagnosis based on parent report.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The treatment team will NOT receive a psychosocial risk summary shortly following diagnosis based on parent report.
Study: NCT02234128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toronto EVLP System™
Description: Extending preservation and assessment time of donor lungs using the Toronto EVLP System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toronto EVLP System™
Description: Extending preservation and assessment time of donor lungs using the Toronto EVLP System
Study: NCT02036307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-enriched
Description: DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA-enriched
Description: EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
Study: NCT04498624

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inverted flap
Description: full thickness macular hole surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peeling internal limiting membrane (ILM)
Description: full thickness macular hole surgery
Study: NCT03097770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/20-CAR vector-transduced T cells
Description: genetically engineered lymphocyte therapy
Study: NCT02549313

Intervention type: PROCEDURE
Intervention: position changes of the head
Description: Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
Study: NCT00766298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: The reduction of kcal/day through implementation of low fat diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and weight loss
Description: Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet.
Study: NCT00566735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Razadyne
Description: The starting dose of study medication is 4 mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg, 2 times a day
Study: NCT03980873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESTEEM (Effective Sikills to Empower Effective Men)
Description: ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (Barlow et al., 2010).~Is an individually-delivered cognitive behavioral treatment with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation abilities; reducing maladaptive cognitive, affective, and behavioral avoidance patterns; and improving motivation and self-efficacy for enacting behavior change
Study: NCT02164240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT05959590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxides 11.2Mg Solution for Injection
Description: the drug will be injected at a single dose of up to 7 mg/Kg and MRI will be performed after 24 hrs.
Study: NCT00964730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: titrated to 50mg three times a day over 9 days and a single dose administered on Day 10

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered three times a day over 9 days and a single dose administered on Day 10
Study: NCT02001818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib, Pegylated interferon alpha-2b, Imatinib
Description: All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
Study: NCT00955825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR
Description: 300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
Study: NCT02751580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Attend a virtual visit via the JeffConnect telehealth app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03109223

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sole source nutrition
Description: Infant formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sole source nutrition
Description: Infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sole source nutrition
Description: Infant formula
Study: NCT01767714

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: 10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: 10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 0.24 mg/kg/day subcutaneous injection
Study: NCT01566240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 (capped at 162mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 \& 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, \& 36.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
Study: NCT01767714

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
Study: NCT00609908

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split skin graft
Description: After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin stretching device
Description: after woundbed preparation the wound is primarily closed by aid of the skin stretching device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serial excision
Description: as much scar as possible is excised, whereafter the wound is closed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin stretching device
Description: after the scar is excised, the wound is primarily closed by aid of the skin stretching device
Study: NCT02726828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal ketamine
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine + ketamine
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
Study: NCT00941655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 460 mg/m\^2 diluted in 2.0 L/m\^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m\^2 over 120 minutes,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 460 mg/m\^2 diluted in 2.0 L/m\^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m\^2 over 120 minutes,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 165 mg/m\^2 IV over 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 165 mg/m\^2 IV over 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m\^2 continuous intravenous over 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m\^2 continuous intravenous over 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: surgery and heated intraperitoneal chemotherapy -20 mg/m\^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m\^2 intravenous over 120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: surgery and heated intraperitoneal chemotherapy -20 mg/m\^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m\^2 intravenous over 120 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy and/or metastasectomy
Description: Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy.
Study: NCT01566240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
Study: NCT02745132

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological evaluation and Brain MRI
Description: This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times.~Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336.
Study: NCT04180800

Intervention type: OTHER
Intervention: Lubben Social Network Scale - 6
Description: One short oral interview to complete the Lubben Social Network Scale in auto-survey, translated in French. It contains 6 questions on 30 points, higher scores are associated with more social engagement, lower scores, specifically under 12/30, are associated with social isolation.

Intervention type: OTHER
Intervention: Lubben Social Network Scale - 6
Description: One short oral interview to complete the Lubben Social Network Scale in auto-survey, translated in French. It contains 6 questions on 30 points, higher scores are associated with more social engagement, lower scores, specifically under 12/30, are associated with social isolation.
Study: NCT01891760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermagraft
Description: Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profore
Description: Four-layer compression bandaging therapy.
Study: NCT03016546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEST-maCARE
Description: Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Condition
Description: The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
Study: NCT00004929

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC-2-KLH vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21